SCHEDULE 13G/A: Union Square Park Entities Disclose 11.44% Stake in Eagle Pharmaceuticals
Beneficial Ownership Report
Union Square Park Partners, LP and affiliated entities have reported a beneficial ownership of 11.44% in Eagle Pharmaceuticals, Inc. common stock as of December 31, 2024.
Summary
- Union Square Park Partners, LP, Union Square Park Capital Management, LLC, Union Square Park GP, LLC, and Leon Zaltzman collectively beneficially own 1,485,677 shares of Eagle Pharmaceuticals, Inc. common stock.
- This aggregate amount represents 11.44% of the outstanding common stock of Eagle Pharmaceuticals, Inc.
- The reporting persons share both voting and dispositive power over all 1,485,677 shares.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a previous filing of beneficial ownership.
- The shares were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G) reporting beneficial ownership, which inherently carries a neutral sentiment. It does not contain forward-looking statements, financial performance, or strategic updates that would typically influence a positive or negative sentiment.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Eagle Pharmaceuticals, a company operating in the pharmaceutical sector. Such a substantial stake by an investment firm can signal confidence in the company's long-term prospects or a strategic positioning within the industry, though the filing itself does not provide specific reasons for the investment beyond regulatory disclosure.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Disclosure | The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11. This indicates a potential interest in board nominations without seeking overall control. | 12/31/2024 | This certification clarifies the intent of the significant shareholder, suggesting a passive investment stance with a potential for engagement on board composition, which could influence corporate governance discussions. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake (11.44%) by Union Square Park entities may be viewed positively by other shareholders as it indicates a large investor's confidence in Eagle Pharmaceuticals. It could also signal potential future engagement on governance matters, particularly board nominations.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date). |
| 02/14/2025 | Date the Schedule 13G/A Amendment No. 2 was signed and filed. |
Keywords
Eagle Pharmaceuticals, Union Square Park Partners, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.